Physician profile
Phillip Mcghee
NPI 1114347747
$2,691.22
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,045 · 2020: $565 · 2021: $25.40 · 2022: $55.86.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $334.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $281.92 | 2019-2020 | |
| Lilly USA, LLC | $278.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.56 | 2019-2022 | |
| Novo Nordisk INC | $226.94 | 2019-2020 | |
| Amgen INC. | $203.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $186.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $180.36 | 2019 | |
| Merck Sharp & Dohme LLC | $171.38 | 2019-2022 | |
| Shire North American Group INC | $112.08 | 2019 | |
| Amarin Pharma, INC. | $101.78 | 2019-2020 | |
| Astellas Pharma US INC | $58.42 | 2019 | |
| Allergan, INC. | $57.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.48 | 2019 | |
| Supernus Pharmaceuticals, INC. | $30.98 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.40 | 2021 | |
| Gilead Sciences, INC. | $19.71 | 2020 | |
| Abbott Laboratories | $19.55 | 2022 | |
| Genentech USA, INC. | $18.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.03 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.52 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.02 | 2019 | |
| Antares Pharma, INC. | $11.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.81 | 2019 | |
| Currax Pharmaceuticals LLC | $7.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Mcghee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.